{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T22:53:44Z","timestamp":1773442424370,"version":"3.50.1"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Patients with post-Lyme disease syndrome (PLDS) report persistent symptoms of pain, fatigue, and\/or concentration and memory disturbances despite antibiotic treatment for Lyme borreliosis. The etiopathogenesis of these symptoms remains unknown and no effective therapies have been identified. We sought to examine the antiborrelia antibody profile in affected patients with the aim of finding clues to the mechanism of the syndrome and its relationship to the original spirochetal infection. Serum specimens from 54 borrelia-seropositive PLDS patients were examined for antibodies to<jats:named-content content-type=\"genus-species\">Borrelia burgdorferi<\/jats:named-content>proteins p18, p25, p28, p30, p31, p34, p39, p41, p45, p58, p66, p93, and VlsE by automated immunoblotting and software-assisted band analysis. The presence of serum antibodies to the 31-kDa band was further investigated by examination of reactivity against purified recombinant OspA protein. Control specimens included sera from 14 borrelia-seropositive individuals with a history of early localized or disseminated Lyme disease who were symptom free (post-Lyme healthy group), as well as 20 healthy individuals without serologic evidence or history of Lyme disease. In comparison to the post-Lyme healthy group, higher frequencies of antibodies to p28 (<jats:italic>P<\/jats:italic>&lt; 0.05), p30 (<jats:italic>P<\/jats:italic>&lt; 0.05), p31 (<jats:italic>P<\/jats:italic>&lt; 0.0001), and p34 (<jats:italic>P<\/jats:italic>&lt; 0.05) proteins were found in the PLDS group. Assessment of antibody reactivity to recombinant OspA confirmed the presence of elevated levels in PLDS patients (<jats:italic>P<\/jats:italic>&lt; 0.005). The described antiborrelia antibody profile in PLDS offers clues about the course of the antecedent infection in affected patients, which may be useful for understanding the pathogenic mechanism of the disease.<\/jats:p>","DOI":"10.1128\/cvi.00002-11","type":"journal-article","created":{"date-parts":[[2011,3,17]],"date-time":"2011-03-17T00:54:33Z","timestamp":1300323273000},"page":"767-771","source":"Crossref","is-referenced-by-count":48,"title":["Anti-Borrelia burgdorferi Antibody Profile in Post-Lyme Disease Syndrome"],"prefix":"10.1128","volume":"18","author":[{"given":"Abhishek","family":"Chandra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary P.","family":"Wormser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana R.","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Latov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Alaedini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2011,3,16]]},"reference":[{"key":"key20180919073512_B1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1128\/CMR.18.3.484-509.2005","article-title":"Diagnosis of lyme borreliosis","volume":"18","author":"Aguero-Rosenfeld","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"key20180919073512_B2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1128\/IAI.67.1.173-181.1999","article-title":"The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 correlates with mild and brief arthritis","volume":"67","author":"Akin","year":"1999","journal-title":"Infect. Immun."},{"key":"key20180919073512_B3","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1086\/345284","article-title":"Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment","volume":"186","author":"Bockenstedt","year":"2002","journal-title":"J. Infect. Dis."},{"key":"key20180919073512_B4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0025-6196(11)60731-3","article-title":"Diagnosis and treatment of Lyme disease","volume":"83","author":"Bratton","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"key20180919073512_B5","first-page":"590","article-title":"Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease","volume":"44","author":"CDC","year":"1995","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"key20180919073512_B6","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.bbi.2010.03.002","article-title":"Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms","volume":"6","author":"Chandra","year":"2010","journal-title":"Brain Behav. Immun."},{"key":"key20180919073512_B7","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1128\/IAI.71.7.4003-4010.2003","article-title":"Host-adapted Borrelia burgdorferi in mice expresses OspA during inflammation","volume":"71","author":"Crowley","year":"2003","journal-title":"Infect. Immun."},{"key":"key20180919073512_B8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0923-2508(97)85121-2","article-title":"Characterization of a 30-kDa Borrelia burgdorferi substrate-binding protein homologue","volume":"147","author":"Das","year":"1996","journal-title":"Res. Microbiol."},{"key":"key20180919073512_B9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/infdis\/167.2.392","article-title":"Western blotting in the serodiagnosis of Lyme disease","volume":"167","author":"Dressler","year":"1993","journal-title":"J. Infect. Dis."},{"key":"key20180919073512_B10","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1212\/01.WNL.0000284604.61160.2d","article-title":"A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy","volume":"70","author":"Fallon","year":"2008","journal-title":"Neurology"},{"key":"key20180919073512_B11","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMra072023","article-title":"A critical appraisal of \u201cchronic Lyme disease.\u201d","volume":"357","author":"Feder","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"key20180919073512_B12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.idc.2007.12.009","article-title":"Nervous system Lyme disease","volume":"22","author":"Halperin","year":"2008","journal-title":"Infect. Dis. Clin. North Am."},{"key":"key20180919073512_B13","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/AAC.01050-07","article-title":"Persistence of Borrelia burgdorferi following antibiotic treatment in mice","volume":"52","author":"Hodzic","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"key20180919073512_B14","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1128\/IAI.61.7.2774-2779.1993","article-title":"Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi","volume":"61","author":"Kalish","year":"1993","journal-title":"Infect. Immun."},{"key":"key20180919073512_B15","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1128\/IAI.63.6.2228-2235.1995","article-title":"Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease","volume":"63","author":"Kalish","year":"1995","journal-title":"Infect. Immun."},{"key":"key20180919073512_B16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM200107123450202","article-title":"Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease","volume":"345","author":"Klempner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"key20180919073512_B17","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1212\/01.WNL.0000071227.23769.9E","article-title":"Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial","volume":"60","author":"Krupp","year":"2003","journal-title":"Neurology"},{"key":"key20180919073512_B18","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1128\/JCM.39.7.2500-2507.2001","article-title":"Genetic heterogeneity of Borrelia burgdorferi sensu lato in the southern United States based on restriction fragment length polymorphism and sequence analysis","volume":"39","author":"Lin","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"key20180919073512_B19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1128\/JCM.30.2.370-376.1992","article-title":"Serodiagnosis of Lyme borreliosis by Western immunoblot: reactivity of various significant antibodies against Borrelia burgdorferi","volume":"30","author":"Ma","year":"1992","journal-title":"J. Clin. Microbiol."},{"key":"key20180919073512_B20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.idc.2007.12.011","article-title":"Chronic Lyme disease: a review","volume":"22","author":"Marques","year":"2008","journal-title":"Infect. Dis. Clin. North Am."},{"key":"key20180919073512_B21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11882-009-0077-3","article-title":"Lyme disease: a review","volume":"10","author":"Marques","year":"2010","journal-title":"Curr. Allergy Asthma Rep."},{"key":"key20180919073512_B22","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/IAI.00189-06","article-title":"Serologic proteome analysis of Borrelia burgdorferi membrane-associated proteins","volume":"74","author":"Nowalk","year":"2006","journal-title":"Infect. Immun."},{"key":"key20180919073512_B23","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0140-6736(03)14798-8","article-title":"Lyme borreliosis","volume":"362","author":"Stanek","year":"2003","journal-title":"Lancet"},{"key":"key20180919073512_B24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM200107123450207","article-title":"Lyme disease","volume":"345","author":"Steere","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"key20180919073512_B25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1172\/JCI21681","article-title":"The emergence of Lyme disease","volume":"113","author":"Steere","year":"2004","journal-title":"J. Clin. Invest."},{"key":"key20180919073512_B26","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1128\/JCM.38.6.2191-2199.2000","article-title":"PCR-based quantification of Borrelia burgdorferi organisms in canine tissues over a 500-day postinfection period","volume":"38","author":"Straubinger","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"key20180919073512_B27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/JCM.35.1.111-116.1997","article-title":"Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment","volume":"35","author":"Straubinger","year":"1997","journal-title":"J. Clin. Microbiol."},{"key":"key20180919073512_B28","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1086\/592279","article-title":"Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease","volume":"198","author":"Wormser","year":"2008","journal-title":"J. Infect. Dis."},{"key":"key20180919073512_B29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/508667","article-title":"The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America","volume":"43","author":"Wormser","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"key20180919073512_B30","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1086\/591529","article-title":"Effect of Borrelia burgdorferi genotype on the sensitivity of C6 and 2-tier testing in North American patients with culture-confirmed Lyme disease","volume":"47","author":"Wormser","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"key20180919073512_B31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1086\/314922","article-title":"Association of specific subtypes of Borrelia burgdorferi with hematogenous dissemination in early Lyme disease","volume":"180","author":"Wormser","year":"1999","journal-title":"J. Infect. Dis."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00002-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:45:33Z","timestamp":1627591533000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00002-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,16]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,5,3]]},"published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1128\/CVI.00002-11"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00002-11","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,16]]}}}